Narsimha Reddy Penthala
Concepts (209)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antineoplastic Agents | 18 | 2021 | 1300 | 2.950 |
Why?
| Indoles | 14 | 2020 | 289 | 2.710 |
Why?
| Sesquiterpenes | 7 | 2021 | 91 | 2.240 |
Why?
| Stilbenes | 6 | 2018 | 65 | 1.450 |
Why?
| Quinuclidines | 5 | 2020 | 42 | 1.290 |
Why?
| Drug Screening Assays, Antitumor | 17 | 2021 | 142 | 1.280 |
Why?
| Cell Line, Tumor | 22 | 2021 | 1550 | 1.220 |
Why?
| Barbiturates | 3 | 2015 | 16 | 1.200 |
Why?
| Molecular Docking Simulation | 9 | 2021 | 83 | 1.170 |
Why?
| Receptor, Cannabinoid, CB1 | 6 | 2020 | 128 | 1.130 |
Why?
| Nuclear Proteins | 3 | 2015 | 252 | 1.050 |
Why?
| Structure-Activity Relationship | 13 | 2021 | 423 | 1.000 |
Why?
| Receptor, Cannabinoid, CB2 | 4 | 2020 | 60 | 1.000 |
Why?
| Molecular Structure | 14 | 2021 | 319 | 0.870 |
Why?
| Cell Proliferation | 12 | 2021 | 1096 | 0.760 |
Why?
| Aza Compounds | 1 | 2020 | 14 | 0.760 |
Why?
| Glioblastoma | 2 | 2021 | 99 | 0.700 |
Why?
| NF-kappa B | 1 | 2021 | 335 | 0.700 |
Why?
| Tubulin | 2 | 2015 | 28 | 0.650 |
Why?
| Dose-Response Relationship, Drug | 13 | 2021 | 1476 | 0.640 |
Why?
| Radiation-Sensitizing Agents | 2 | 2015 | 55 | 0.630 |
Why?
| DNA Breaks, Double-Stranded | 2 | 2015 | 78 | 0.630 |
Why?
| Binding Sites | 5 | 2021 | 440 | 0.570 |
Why?
| Vesicular Monoamine Transport Proteins | 2 | 2013 | 49 | 0.550 |
Why?
| Tubulin Modulators | 2 | 2016 | 40 | 0.540 |
Why?
| Pyrimidines | 3 | 2018 | 196 | 0.540 |
Why?
| Heterocyclic Compounds | 2 | 2014 | 30 | 0.540 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 446 | 0.540 |
Why?
| Cell Survival | 2 | 2015 | 657 | 0.480 |
Why?
| Lobeline | 2 | 2013 | 38 | 0.470 |
Why?
| Blotting, Western | 1 | 2015 | 683 | 0.460 |
Why?
| Tryptophan | 2 | 2011 | 102 | 0.460 |
Why?
| Cell Cycle | 1 | 2014 | 275 | 0.450 |
Why?
| Pyrrolidines | 1 | 2013 | 88 | 0.410 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 175 | 0.400 |
Why?
| Imidazolidines | 1 | 2010 | 5 | 0.380 |
Why?
| Morphine Derivatives | 2 | 2021 | 30 | 0.350 |
Why?
| Humans | 31 | 2021 | 54284 | 0.350 |
Why?
| Naphthalenes | 3 | 2019 | 126 | 0.340 |
Why?
| Imidazoles | 1 | 2009 | 142 | 0.330 |
Why?
| DNA-Directed DNA Polymerase | 2 | 2019 | 96 | 0.310 |
Why?
| Animals | 18 | 2021 | 14385 | 0.300 |
Why?
| Phosphorylation | 2 | 2021 | 614 | 0.290 |
Why?
| Ligands | 4 | 2020 | 230 | 0.280 |
Why?
| Rats | 7 | 2021 | 3415 | 0.270 |
Why?
| Hematologic Neoplasms | 2 | 2017 | 99 | 0.260 |
Why?
| Protein Structure, Tertiary | 2 | 2015 | 289 | 0.250 |
Why?
| Carboxylic Acids | 2 | 2017 | 17 | 0.240 |
Why?
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 87 | 0.240 |
Why?
| Thiobarbiturates | 3 | 2018 | 23 | 0.240 |
Why?
| Oocytes | 2 | 2014 | 94 | 0.240 |
Why?
| Amyloid beta-Peptides | 2 | 2021 | 82 | 0.230 |
Why?
| Peptide Fragments | 2 | 2021 | 242 | 0.220 |
Why?
| Drug Design | 2 | 2020 | 133 | 0.220 |
Why?
| Dopamine | 2 | 2013 | 190 | 0.210 |
Why?
| Drug Tolerance | 2 | 2019 | 60 | 0.210 |
Why?
| Cannabinoids | 2 | 2020 | 108 | 0.210 |
Why?
| Biological Specimen Banks | 1 | 2021 | 21 | 0.200 |
Why?
| Transcription Factor RelA | 1 | 2021 | 30 | 0.200 |
Why?
| Benzylamines | 1 | 2021 | 18 | 0.200 |
Why?
| Thermodynamics | 1 | 2021 | 43 | 0.200 |
Why?
| Cholinesterase Inhibitors | 1 | 2021 | 25 | 0.200 |
Why?
| Lactones | 1 | 2021 | 27 | 0.200 |
Why?
| Organoids | 1 | 2021 | 41 | 0.200 |
Why?
| Alkaloids | 1 | 2021 | 37 | 0.200 |
Why?
| Cannabinoid Receptor Agonists | 2 | 2020 | 48 | 0.200 |
Why?
| Thiadiazoles | 1 | 2020 | 15 | 0.190 |
Why?
| Oxyquinoline | 1 | 2020 | 7 | 0.190 |
Why?
| Drug Discovery | 1 | 2021 | 90 | 0.190 |
Why?
| Small Molecule Libraries | 3 | 2018 | 72 | 0.190 |
Why?
| Chelating Agents | 1 | 2020 | 28 | 0.190 |
Why?
| Cellulose, Oxidized | 1 | 2020 | 3 | 0.190 |
Why?
| Sulfuric Acids | 1 | 2020 | 8 | 0.190 |
Why?
| Morphine | 1 | 2021 | 96 | 0.190 |
Why?
| Neuroprotective Agents | 1 | 2021 | 125 | 0.180 |
Why?
| Piperidines | 1 | 2020 | 103 | 0.180 |
Why?
| Nanostructures | 1 | 2020 | 53 | 0.180 |
Why?
| Apoptosis | 2 | 2015 | 1300 | 0.170 |
Why?
| Tumor Stem Cell Assay | 2 | 2015 | 21 | 0.170 |
Why?
| Tetrazoles | 1 | 2018 | 43 | 0.170 |
Why?
| RNA Helicases | 1 | 2018 | 31 | 0.170 |
Why?
| Receptors, Opioid, delta | 1 | 2018 | 25 | 0.160 |
Why?
| Protein Binding | 3 | 2020 | 736 | 0.160 |
Why?
| Viral Nonstructural Proteins | 1 | 2018 | 61 | 0.160 |
Why?
| Receptors, Opioid, mu | 1 | 2018 | 47 | 0.160 |
Why?
| Cisplatin | 2 | 2018 | 352 | 0.160 |
Why?
| Brain Neoplasms | 1 | 2021 | 284 | 0.160 |
Why?
| Xenopus | 2 | 2014 | 47 | 0.160 |
Why?
| Mammary Neoplasms, Animal | 1 | 2017 | 38 | 0.150 |
Why?
| Cell Line | 3 | 2015 | 1153 | 0.150 |
Why?
| GTP-Binding Proteins | 1 | 2017 | 94 | 0.150 |
Why?
| Esters | 1 | 2017 | 25 | 0.150 |
Why?
| Alzheimer Disease | 1 | 2021 | 367 | 0.150 |
Why?
| Dengue Virus | 1 | 2016 | 21 | 0.140 |
Why?
| Synaptic Vesicles | 2 | 2013 | 19 | 0.140 |
Why?
| Dioxanes | 1 | 2016 | 10 | 0.140 |
Why?
| Rats, Inbred F344 | 1 | 2016 | 209 | 0.140 |
Why?
| Acetonitriles | 1 | 2016 | 7 | 0.140 |
Why?
| Fibroblasts | 2 | 2015 | 386 | 0.140 |
Why?
| Benzothiazoles | 1 | 2015 | 11 | 0.130 |
Why?
| Benzofurans | 1 | 2015 | 18 | 0.130 |
Why?
| Centrosome | 1 | 2015 | 11 | 0.130 |
Why?
| Benzodioxoles | 1 | 2016 | 56 | 0.130 |
Why?
| Thiophenes | 1 | 2015 | 37 | 0.130 |
Why?
| Ubiquitin | 1 | 2015 | 51 | 0.130 |
Why?
| Naltrexone | 2 | 2018 | 62 | 0.130 |
Why?
| Colchicine | 1 | 2015 | 35 | 0.130 |
Why?
| Neoplasms | 3 | 2018 | 1316 | 0.130 |
Why?
| Antiviral Agents | 1 | 2016 | 188 | 0.130 |
Why?
| Gamma Rays | 1 | 2015 | 56 | 0.130 |
Why?
| Enzyme Assays | 1 | 2014 | 12 | 0.130 |
Why?
| Triazoles | 1 | 2015 | 120 | 0.130 |
Why?
| High-Throughput Screening Assays | 1 | 2014 | 37 | 0.130 |
Why?
| Narcotic Antagonists | 2 | 2018 | 127 | 0.130 |
Why?
| Deoxyribonuclease I | 1 | 2014 | 41 | 0.120 |
Why?
| Endodeoxyribonucleases | 1 | 2014 | 55 | 0.120 |
Why?
| Positron-Emission Tomography | 1 | 2016 | 322 | 0.120 |
Why?
| Cell Nucleus | 1 | 2015 | 203 | 0.120 |
Why?
| Carbamates | 1 | 2014 | 21 | 0.120 |
Why?
| Chromatin | 1 | 2015 | 156 | 0.120 |
Why?
| Azetidines | 1 | 2013 | 7 | 0.120 |
Why?
| Radiation Tolerance | 1 | 2014 | 86 | 0.120 |
Why?
| Mitosis | 1 | 2014 | 106 | 0.120 |
Why?
| Molecular Targeted Therapy | 1 | 2014 | 128 | 0.120 |
Why?
| Tetrabenazine | 1 | 2013 | 12 | 0.110 |
Why?
| Analgesics, Opioid | 1 | 2018 | 501 | 0.110 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2013 | 61 | 0.110 |
Why?
| Sulfhydryl Compounds | 1 | 2012 | 19 | 0.110 |
Why?
| DNA Repair | 1 | 2014 | 202 | 0.110 |
Why?
| Neoplasm Proteins | 1 | 2014 | 359 | 0.100 |
Why?
| Stereoisomerism | 3 | 2016 | 106 | 0.100 |
Why?
| Needles | 1 | 2010 | 30 | 0.090 |
Why?
| Prodrugs | 1 | 2010 | 33 | 0.090 |
Why?
| Microwaves | 1 | 2009 | 12 | 0.090 |
Why?
| Mice | 5 | 2019 | 6413 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2017 | 1248 | 0.080 |
Why?
| Inhibitory Concentration 50 | 2 | 2019 | 80 | 0.070 |
Why?
| Cricetulus | 2 | 2017 | 102 | 0.070 |
Why?
| CHO Cells | 2 | 2017 | 123 | 0.070 |
Why?
| Rats, Sprague-Dawley | 2 | 2021 | 1663 | 0.070 |
Why?
| Kinetics | 2 | 2014 | 692 | 0.050 |
Why?
| Spheroids, Cellular | 1 | 2021 | 26 | 0.050 |
Why?
| Electrophorus | 1 | 2021 | 5 | 0.050 |
Why?
| Butyrylcholinesterase | 1 | 2021 | 8 | 0.050 |
Why?
| Tissue Culture Techniques | 1 | 2021 | 46 | 0.050 |
Why?
| Acetylcholinesterase | 1 | 2021 | 21 | 0.050 |
Why?
| Horses | 1 | 2021 | 51 | 0.050 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2020 | 20 | 0.050 |
Why?
| Catalytic Domain | 1 | 2020 | 62 | 0.050 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 295 | 0.050 |
Why?
| Densitometry | 1 | 2020 | 17 | 0.050 |
Why?
| X-Ray Diffraction | 1 | 2020 | 21 | 0.050 |
Why?
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 19 | 0.050 |
Why?
| Protein Structure, Secondary | 1 | 2020 | 99 | 0.050 |
Why?
| Tensile Strength | 1 | 2020 | 33 | 0.050 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 42 | 0.050 |
Why?
| Protein Conformation | 1 | 2020 | 226 | 0.050 |
Why?
| HEK293 Cells | 1 | 2020 | 245 | 0.040 |
Why?
| Alkylation | 1 | 2019 | 10 | 0.040 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.040 |
Why?
| Nociception | 1 | 2019 | 13 | 0.040 |
Why?
| Models, Molecular | 1 | 2020 | 423 | 0.040 |
Why?
| Male | 4 | 2021 | 27334 | 0.040 |
Why?
| Discrimination Learning | 1 | 2018 | 49 | 0.040 |
Why?
| Cyclohexanols | 1 | 2017 | 23 | 0.040 |
Why?
| Hepacivirus | 1 | 2018 | 127 | 0.040 |
Why?
| Conditioning, Operant | 1 | 2018 | 106 | 0.040 |
Why?
| Substance Withdrawal Syndrome | 1 | 2018 | 179 | 0.040 |
Why?
| DNA Damage | 1 | 2019 | 357 | 0.040 |
Why?
| Drug Repositioning | 1 | 2016 | 11 | 0.040 |
Why?
| Gliosarcoma | 1 | 2015 | 4 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2016 | 158 | 0.030 |
Why?
| Dimerization | 1 | 2015 | 59 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2015 | 65 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2017 | 656 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2016 | 290 | 0.030 |
Why?
| Virus Replication | 1 | 2016 | 143 | 0.030 |
Why?
| Taxoids | 1 | 2014 | 45 | 0.030 |
Why?
| Tanacetum parthenium | 1 | 2014 | 3 | 0.030 |
Why?
| Drug Resistance | 1 | 2014 | 74 | 0.030 |
Why?
| Rad51 Recombinase | 1 | 2014 | 21 | 0.030 |
Why?
| Chemical Phenomena | 1 | 2014 | 18 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 50 | 0.030 |
Why?
| Female | 2 | 2017 | 28441 | 0.030 |
Why?
| Drug Inverse Agonism | 1 | 2014 | 18 | 0.030 |
Why?
| G2 Phase | 1 | 2014 | 15 | 0.030 |
Why?
| Substrate Specificity | 1 | 2014 | 209 | 0.030 |
Why?
| Protein Biosynthesis | 1 | 2016 | 273 | 0.030 |
Why?
| Cricetinae | 1 | 2014 | 209 | 0.030 |
Why?
| Enzyme Activation | 1 | 2014 | 329 | 0.030 |
Why?
| Opioid-Related Disorders | 1 | 2018 | 367 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 2015 | 215 | 0.030 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2015 | 191 | 0.030 |
Why?
| Tritium | 1 | 2013 | 53 | 0.030 |
Why?
| Mice, Nude | 1 | 2014 | 283 | 0.030 |
Why?
| Isomerism | 1 | 2013 | 24 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2014 | 477 | 0.030 |
Why?
| Brain | 1 | 2021 | 1387 | 0.030 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 164 | 0.030 |
Why?
| Time Factors | 1 | 2019 | 3213 | 0.030 |
Why?
| Histones | 1 | 2014 | 335 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2014 | 1304 | 0.020 |
Why?
| Viscosity | 1 | 2010 | 9 | 0.020 |
Why?
| Swine, Miniature | 1 | 2010 | 17 | 0.020 |
Why?
| Solubility | 1 | 2010 | 75 | 0.020 |
Why?
| Administration, Cutaneous | 1 | 2010 | 63 | 0.020 |
Why?
| Swine | 1 | 2010 | 431 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2014 | 1999 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2014 | 642 | 0.020 |
Why?
|
|
Penthala's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|